Increased rate of positive biopsies using a combination of MR-Tomography, spectroscopy and diffusion-weighted magnetic resonance imaging prior to prostate biopsies in patients with persistent elevated prostate-specific antigen values: A retrospective analysis

Urology Annals

Volumn 5, Issue 2, 2013, Pages 76-80

  Lunacek, A ^a   Simon, J ^a   Bernt, R ^a   Huber, M ^a   Plas, E ^a   Mrstik, C ^a  

^a HANUSCH HOSPITAL   (Austria)

Author keywords

Biopsy; detection; magnetic resonance imaging; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER STAGING; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE GUIDED BIOPSY; INTERMETHOD COMPARISON; MAGNETIC RESONANCE TOMOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; RETROSPECTIVE STUDY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

EID: 84876931886     PISSN: 09747796     EISSN: 09747834     Source Type: Journal    
DOI: 10.4103/0974-7796.110001     Document Type: Article

References (20)

1. Frauscher F, Klauser A, Halpern EJ, Horninger W, Bartsch G. Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 2001;357:1849-50.
2. Roy C, Buy X, Lang H, Saussine C, Jacqmin D. Contrast enhanced color Doppler endorectal sonography of prostate: Efficiency for detecting peripheral Zone tumors and role for biopsy procedure. J Urol 2003;170:69-72.
3. Lawrentschuk N, Fleshner N. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int 2009;103:730-3.
4. Sciarra A, Salciccia S, Panebianco V. Proton spectroscopic and dynamic contrast-enhanced magnetic resonance: A modern approach in prostate cancer imaging. Eur Urol 2008;54:485-8.
5. Bonekamp D, Jacobs MA, El-Khouli R, Stoianovicic D, Macura KJ. Advancements in MR imaging of the prostate: From diagnosis to interventions. Radiographics 2011;3:677-703.
6. Mueller-Lisse UG, Scherr M. 1H magnetic resonance spectroscopy of the prostate. Radiologe 2003;43:481-8.
7. Puppo P, Introini C, Calvi P, Naselli A. Role of transurethral resection of the prostate and biopsy of the peripheral zone in the same session after repeated negative biopsies in the diagnosis of prostate cancer. Eur Urol 2006;49:873-8.
8. Puppo P. Repeated negative prostate biopsies with persistently elevated or rising PSA: A modern urologic dilemma. Eur Urol 2007;52:639-41.
9. Djavan B, Mazal P, Zlotta A, Wammack R, Ravery V, Remzi M, et al. Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European Prostate Cancer Detection study. Prostate 2001;47:111-7.
10. Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, et al. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate 2004;58:277-82.
11. Stricker HJ, Ruddock LJ, Wan J, Belville WD. Detection of non-palpable prostate cancer. A mathematical and laboratory model. Br J Urol 1993;71:43-6.
12. Patel A. Finding a balanced strategy in prostate cancer diagnosis for case detection by prostate needle biopsy at first presentation: “All for more cores and more cores for all” or individualised sampling regimens? Which way forward? Eur Urol 2007;52:313-5.
13. Guichard G, Larré S, Gallina A, Lazar A, Faucon H, Chemama S, et al. Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007;52:430-5.
14. Frauscher F, Klauser A, Volgger H, Halpern EJ, Pallwein L, Steiner H, et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: Impact on prostate cancer detection. J Urol 2002;167:1648-52.
15. Hricak H: Imaging prostate cancer. J Urol 1999;162:1329-30.
16. Fütterer JJ, Heijmink SW, Scheenen TW, Veltman J, Huisman HJ, Vos P, et al. Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology 2006;241:449-58.
17. Mazaheri Y, Shukla-DaveA, Hricak H, Fine SW, Zhang J, Inurrigarro G, et al. Prostate cancer identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging – correlation with pathologic findings. Radiology 2008;246:480-8.
18. Mullerad M, Hricak H, Kuroiwa K, Pucar D, Chen HN, Kattan MW, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005;174:2158-63.
19. Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197-206.
20. Pinto F, Totaro A, Calarco A, Sacco E, Volpe A, Racioppi M, et al. Imaging in prostate cancer diagnosis: Present role and future perspectives. Urol Int 2011;86:373-82.